Today, the pharma company GlaxoSmithKline (GSK) announced a five-year, $25-million-plus collaborative agreement with the Harvard Stem Cell Institute to develop new methods for screening drugs with stem cells.
“GSK believes stem cell science has great potential to aid the discovery of new medicines by improving the screening, identification, and development of new compounds,” said Patrick Vallance, head of drug discovery at GSK, in a statement released by the company.
Big Pharma has mostly shied away from investing in stem-cell research. But drug screening, which some scientists say is likely to be one of the biggest near-term benefits of stem cells, is a growing area of interest.
Because stem cells can be differentiated into any type of cell in the body, they present an ideal source for screening. For example, scientists can determine how a candidate heart-disease drug affects heart cells and also look for potential side effects in liver or other cell types.
The time appears ripe for investing, because scientists can now use new reprogramming techniques to develop stem cells from patients with specific diseases. (While no one has yet reported this, word among stem-cell researchers is that it has been done.) That means they can make nerve cells from stem cells derived from an Alzheimer’s patient and then examine how candidate Alzheimer’s drugs affect the diseased cells.
This new data poisoning tool lets artists fight back against generative AI
The tool, called Nightshade, messes up training data in ways that could cause serious damage to image-generating AI models.
The Biggest Questions: What is death?
New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.
Rogue superintelligence and merging with machines: Inside the mind of OpenAI’s chief scientist
An exclusive conversation with Ilya Sutskever on his fears for the future of AI and why they’ve made him change the focus of his life’s work.
How to fix the internet
If we want online discourse to improve, we need to move beyond the big platforms.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.